Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors
暂无分享,去创建一个
Natale Cascinelli | Rosaria Bufalino | Silvana Pilotti | S. Ménard | N. Cascinelli | F. Rilke | S. Pilotti | P. Casalini | G. Tomasic | R. Bufalino | F. Perrone | M. Colnaghi | Patrizia Casalini | Sylvie Ménard | Franco Rilke | Gorana Tomasic | Franco Perrone | Chiara Longhi | M. Ines Colnaghi | C. Longhi
[1] W. McGuire,et al. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. , 1992, The New England journal of medicine.
[2] U. Veronesi,et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. , 1994, Journal of the National Cancer Institute.
[3] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[4] W. McGuire,et al. Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. , 1992, Annual review of medicine.
[5] G. Clark. Do we really need prognostic factors for breast cancer? , 2004, Breast Cancer Research and Treatment.
[6] D N Poller,et al. Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team. , 1993, Clinical radiology.
[7] U. Veronesi,et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. , 1993, Journal of the National Cancer Institute.
[8] Johannes Gerdes,et al. Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.
[9] W. Kast,et al. Potential immunogenicity of oncogene and tumor suppressor gene products. , 1993, Current opinion in immunology.
[10] S. Pinder,et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma , 1995, Histopathology.
[11] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[12] A. Bianco,et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Ménard,et al. Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression , 1992, Clinical & Experimental Metastasis.
[14] S. Ménard,et al. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] F. Crivelli,et al. Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. , 1993, American journal of clinical pathology.
[16] F. Sarkar,et al. Concurrent abnormal expression of ERBB-2, EGFR, and p53 genes and clinical disease progression of breast carcinoma , 2004, Breast Cancer Research and Treatment.
[17] Trevor Hastie,et al. The Geometric Interpretation of Correspondence Analysis , 1987 .
[18] S. Ménard,et al. Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.
[19] D. Birnbaum,et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. , 1994, Anticancer research.
[20] S. Ménard,et al. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. , 1993, Cancer research.
[21] Rosalba Miceli,et al. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy , 2005, Breast Cancer Research and Treatment.
[22] J. Torhorst,et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.